GlassScriptPhysician profile
Molly Jane Lowe
NPI 1003589276
$3,462.09
in general payments reported to CMS, 2019-2025
22 companies · $719 in 2025
The $719 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $885 · 2023: $855 · 2024: $774 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $563.33 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $526.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $270.23 | 2022-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.06 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $249.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $235.61 | 2022-2025 | |
| Lilly USA, LLC | $225.63 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $204.27 | 2021-2022 | |
| Amgen INC. | $147.07 | 2021-2025 | Repatha, Otezla, Evenity |
| Mylan Specialty L.P. | $146.22 | 2021-2024 | Yupelri, Yupelri |
| Abbott Laboratories | $111.43 | 2023 | Diamondback Peripheral |
| Exact Sciences Corporation | $104.36 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $92.09 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.24 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $69.82 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $56.78 | 2024 | Gemtesa |
| Dexcom, INC. | $36.89 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $23.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.98 | 2024 | Austedo Xr |
| Optos, INC. | $17.54 | 2021 | |
| Lundbeck LLC | $16.98 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.